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Abstract
Background: Mitochondrial function is impaired in Parkinson’s disease (PD) and may contribute to the
pathogenesis of PD, but the causes of mitochondrial impairment in PD are unknown. Mitochondrial dysfunction is
recapitulated in cell lines expressing mitochondrial DNA (mtDNA) from PD patients, implicating mtDNA variants or
mutations, though the role of mtDNA variants or mutations in PD risk remains unclear. We investigated the
potential contribution of mtDNA variants or mutations to the risk of PD.
Methods: We examined the possibility of a maternal inheritance bias as well as the association between
mitochondrial haplogroups and maternal inheritance and disease risk in a case-control study of 168 multiplex PD
families in which the proband and one parent were diagnosed with PD. 2-tailed Fisher Exact Tests and McNemar’s
tests were used to compare allele frequencies, and a t-test to compare ages of onset.
Results: The frequency of affected mothers of the proband with PD (83/167, 49.4%) was not significantly different
from the frequency of affected females of the proband generation (115/259, 44.4%) (Odds Ratio 1.22; 95%CI 0.83 -
1.81). After correcting for multiple tests, there were no significant differences in the frequencies of mitochondrial
haplogroups or of the 10398G complex I gene polymorphism in PD patients compared to controls, and no
significant associations with age of onset of PD. Mitochondrial haplogroup and 10398G polymorphism frequencies
were similar in probands having an affected father as compared to probands having an affected mother.
Conclusions: These data fail to demonstrate a bias towards maternal inheritance in familial PD. Consistent with
this, we find no association of common haplogroup-defining mtDNA variants or for the 10398G variant with the
risk of PD. However, these data do not exclude a role for mtDNA variants in other populations, and it remains
possible that other inherited mitochondrial DNA variants, or somatic mDNA mutations, contribute to the risk of
familial PD.
Background
Mitochondrial complex I is impaired in platelets [1] and
in the substantia nigra [2] in PD. Inhibitors of complex
I induce parkinsonism in a variety of animal models
[3,4], suggesting that complex I deficiency may contri-
bute to the pathogenesis of PD. Evidence in support of
the possibility that mtDNA variants may play a role in
PD is the reported bias towards maternal inheritance of
PD [5,6], though a maternal bias has not been detected
in all studies [7,8]. Additional evidence comes from stu-
dies of cell lines expressing mtDNA from PD patients,
which recapitulate the complex I defect found in PD,
suggesting that mtDNA mutations account for the com-
plex I dysfunction [9-11]. A multigenerational family has
been reported with maternally inherited PD associated
with a mitochondrial complex I defect in cybrids created
from affected family members, although specific mtDNA
mutations were not reported [11]. Other rare families
with parkinsonism associated with mtDNA point muta-
tions or multiple mtDNA deletions have been reported
[12-18]; however, extensive searches for mtDNA muta-
tions in PD patients have failed to reveal clearly patho-
genic mutations in the vast majority of patients [19-21].
Heteroplasmic mitochondrial ND5 gene mutations have
been associated with PD [22,23], but these mutations
were present at very low levels and so are unlikely to be
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of functional significance. Certain mitochondrial hap-
logroups have been reported to be associated with the
risk of PD, but these studies have yielded variable results
[24-31]. A common variant in a mitochondrial complex
I gene, 10398G, has been reported to be less frequent in
PD patients, suggesting a protective effect [25,32]; how-
ever, this has not been consistently confirmed across
studies [19,24]. Thus, the contribution of mtDNA var-
iants to PD risk remains unclear. Furthermore, prior
studies have not addressed the possibility of an associa-
tion of mtDNA variants with other clinical features,
such as age of onset of PD.
We sought to investigate the association of mtDNA
variants with the risk of PD and with the age of onset of
PD by taking advantage of a unique cohort of familial
PD subjects. We focused on the subset of families in
which the proband and either the mother or the father
were diagnosed with PD. This allowed us to test for a
maternal bias in the inheritance of PD and also to test




As part of an ongoing genetic study recruiting siblings
diagnosed with PD, 654 multiplex PD families were
ascertained. All available affected individuals were seen
by a movement disorder specialist at one of 59 Parkin-
son Study Group sites. A standardized clinical assess-
ment was completed including the validated Unified
Parkinson’s Disease Rating Scale (UPDRS) Parts II & III
[33]. A diagnostic checklist with inclusion and exclusion
criteria based on previously described clinicopathological
correlates [34] was used as previously described [35].
Peripheral blood for DNA extraction was obtained from
all individuals after obtaining written informed consent
approved by each institution’s review board.
To explore the role of inherited mitochondrial factors,
a subset of families was analyzed which included a pro-
band with PD that was verified by direct clinical exami-
nation and with either a mother or a father (but not
both) diagnosed with PD (n = 168). These 168 families
excluded families with either two parkin mutations
(homozygous or compound heterozygous) or a LRRK2
mutation. Families in which both the mother and the
father were diagnosed with PD were also excluded from
analyses (n = 11).
Control samples (n = 895) were obtained from the
NINDS Human Genetics Resource Center at the Coriell
Institute Coriell Cell Repositories (Camden, NJ). These
control samples as well as a single individual from each
of 488 of the Parkinson’s Research: The Organized
Genetics Initiative (PROGENI) families were genotyped
at the Center for Inherited Disease Research (CIDR)
using the Illumina HumanCNV370 version1_C Bead-
Chips (Illumina, San Diego, CA, USA) and the Illumina
Infinium II assay protocol [36] as part of a study to
identify genetic risk factors contributing to PD suscept-
ibility [37]. This genome-wide data was then used to
match cases with controls based on age, gender, and
ethnicity as determined by the multidimensional scaling
(MDS) algorithm implemented in PLINK [38]. As
described previously [37], a MDS analysis identified
individuals with African, Asian or Hispanic decent.
These individuals were removed to avoid confounding
issues of population stratification, and the MDS analyses
were repeated using only those individuals who were
both self-declared to be non-Hispanic Caucasian and
who clustered as non-Hispanic Caucasians. The first
two components from this second MDS analysis yielded
one large cluster with Northwestern European ancestry,
a smaller cluster with Ashkenazi Jewish ancestry, and a
continuum of individuals in between with an origin
from Southern Europe and the Middle East (see Fig-
ure 1). It is these first two components that were used
to match cases with controls.
Cases and controls were matched in four dimensional
space (gender, age, and two MDS components) using
the following algorithm. Gender was coded as 0 and 1,
the age distribution was normalized and multiplied by 4,
and each of the first two MDS components were nor-
malized and multiplied by 8. The Euclidean distance
between all possible cases and all possible controls was
then computed, and the minimum distance to a control
was determined for each case. The case-control pair
with the minimum distance was flagged and declared a
final match. The selection process was then repeated
iteratively with the remaining individuals, flagging the
pair with the minimum distance, until all cases were
matched to a control. The distribution of distances
between cases and their final matched control sample
was reviewed and those pairs that were beyond 3 stan-
dard deviations from the mean were not included in the
paired analyses (n = 10). The weights used (1, 4 and 8)
were selected to balance the contribution of each factor
and minimize the number of outliers; without these
weights, gender dominated the matching process at the
expense of the ethnicity components. Demographics of
cases and controls are indicated in Table 1.
Genotyping
To allow haplogroup identification, 12 SNPs were geno-
typed. These included 10 SNPs genotyped in previous
reports that are associated with particular haplogroups
[32]: 1719A (Haplogroups I and X), 4580A (Haplogroup
V), 7028C (Haplogroup H), 8251A (Haplogroups I and
W), 9055A (Haplogroup K), 10398G (Haplogroups I, J,
and K), 12308G (Haplogroups K and U), 13368A
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(Haplogroup T), 13708A (Haplogroup J), and 16391A
(Haplogroup I), as well as two additional SNPs (10400T
and 16390A) that were included to reduce the number
of ambiguous haplogroups. Genotyping was performed
by use of custom TaqMan SNP Genotyping assays
(Applied Biosystems, Foster City, CA) and restriction
digests. Taqman assays were designed using ABI’s Cus-
tom Taqman Assay Design Tool. SNPs for which Taq-
man assays were used (1719A, 4580A, 7028C, 9055A,
12308G, 13368A, 13708A) were assayed using 30 ng of
genomic DNA and ABI’s Taqman Genotyping Master
Mix. The assays were run on thermocyclers according
to manufacturer instructions and post-read on a 7300
Real Time PCR System using SDS software version 1.3.1
(Applied Biosystems, Foster City, CA). SNPs for which
restriction digests were used (8251A, 10398G, 16391A)
were assayed by using 40 ng of genomic DNA for PCR
amplification followed by restriction digest with enzymes
HaeIII (8251A), DdeI/AluI (10398G), or BamHI/HinfI
(16391A) according to manufacturer instructions (New
England Biolabs, Ipswich, MA). Restriction digest pro-
ducts were electrophoresed through a 4% Genepure
Sieve GQA agarose gel (ISC BioExpress, Kaysville, UT)
and visualized by ethidium bromide staining. The two
additional SNPs assayed (10400T and 16390A) were
assayed by Taqman as described above. Because some
SNPs do not tag their haplotypes exclusively, alleles that
were seen in less than 95% of a reference panel of 560
Figure 1 Case-control pairings. All 488 PROGENI cases that were recently included in a genomewide association study [37] were matched to a
control by minimizing the distance between each case-control pair in four dimensional space (age, gender, and two ethnicity components).
Figure 1 shows the pairs in two dimensional space (just the ethnicity components). Those with pairings with 4-dimensional distances greater
than three standard deviations from the mean were not included in the analyses (color coded in orange). Based on those samples where
religion and country of origin was known to be homogeneous for all four grandparents (~15% of samples), we have inferred that those samples
in region A represent Northwestern European ancestry, region B represents Southern European and the Middle Eastern ancestry, and region C






Age at onset (cases) or exam (controls) 61.8 ± 10.2 (range: 21-84) 60.7 ± 11.0 (range: 25-86)
Non-Hispanic Caucasian 100% 100%
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individuals [39] were not required for their respective
haplotypes. These include 8251A for haplogroup I,
10398G for haplogroups I/J/K, and the major allele
13708G for haplogroup X (Table 2). All haplogroups
could still be unambiguously defined when there was no
missing data. Individuals that had one or more missing
genotype and their matching case/control were not
included in analysis (n = 10 pairs).
Statistical methods
Proportions of male versus female PD subjects in the par-
ent versus offspring generations were compared using a
2-tailed Fisher’s exact test. A 2-tailed Fisher’s exact test was
also used for comparison of the frequencies of mitochon-
drial SNP and haplogroups between PD cases and controls,
and also for comparison of the mitochondrial SNP and
haplogroup frequencies between PD cases with an affected
mother and those with an affected father. In order to take
advantage of the paired study design, the data also were
analyzed using the more powerful McNemar’s test. In this
test the number of discordant matched pairs are deter-
mined, such that b = the number of pairs where the case is
a carrier of the variant and the matched control is not and
c = the number of pairs where the case is not a carrier and
the control is. If b is significantly greater than c, then the
null hypothesis is rejected, suggesting that the allele
increases risk for disease. When b+c < 25, then significance
(the p-value) is determined by the sign test (binomial dis-
tribution) instead of McNemar’s test.
Age at onset was compared between carriers and non
carriers of each variant using an independent t-test.
Since all siblings share the same mitochondrial SNP
alleles, and therefore haplogroups, we repeated these
analyses substituting the mean age at onset of all
affected siblings in a nuclear family for the age at onset
of the individual genotyped. The number of affected sib-
lings in a family ranged from 1 to 5.
Results
A total of 168 families were identified in which one par-
ent and one or more offspring were affected with PD,
with at least one offspring having had their PD diagnosis
verified by direct clinical examination. There were 259
siblings among the offspring generation of these
families, of which 115 (44.4%) were females. Among the
168 parents with PD, 83 (49.4%) were females (mothers),
which was not significantly different compared to the
offspring generation (2-tailed Fisher exact p = 0.32).
Next, we assessed the association of mitochondrial
haplogroups with the risk of maternal transmission of
PD. The most common European mitochondrial hap-
logroups were defined as shown in Table 2. There were
no significant differences in frequencies of any indivi-
dual haplogroup among families in which the father had
PD compared to families in which the mother had PD
(Table 3).
When allele frequencies were compared between cases
and controls (Table 3), haplogroup X showed a trend
toward greater disease risk (p = 0.01); however, this
association was not significant after controlling for mul-
tiple testing (even when only considering testing each of
the ten haplogroups separately (rather than in combina-
tions), which requires a Bonferroni correction of alpha =
0.005). The frequencies of haplogroup clusters pre-
viously reported in some studies to be associated with
an increased (JT [31]; JTIWX [26]) or reduced (UKJT
[27,40]) risk of PD, were not significantly different
between PD and control subjects in the population of
subjects reported here. There were no significant asso-
ciations of the 10398G SNP or haplogroups (individually
or in clusters) with the age of onset of PD (Table 4).
When analyzing the mean age at onset within a nuclear
family, carriers of haplogroup U tended to have an ear-
lier PD onset (p = 0.03). A similar trend was seen for a
SNP that tags haplotype U (12308G; p = 0.01). These
Table 2 Classification of Haplogroups
Haplo-group 1719 4580 7028 8251 9055 10398 10400 12308 13368 13708 16391
H 99% G G 95% C G 99.6% A A C A G 98% A G
I A G T 93% A G 93% G C A G G A
J 97% G G T G G 88% G C A G A G
K G G T G A 70% G C G G G G
T 98% G G T G G A C A A G G
U G G T G G A C G G 98% A G
V G A T G G A C A G G G
W G G T A G A C A G G G
X A G T G G A C A G 45% A G
M G G T G G G T A G G G
Those tag SNPs present on less than 95% of reference haplotypes [39] are listed in bold and were not required to define the corresponding haplogroup. Given
no missing data at the other loci, haplogroups could still be unambiguously defined in all instances.
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associations were not significant after correcting for
multiple testing.
Discussion
This study of the PROGENI subjects represents the first
to report data on mitochondrial genetic variants in con-
junction with maternal inheritance in a large group of
familial PD cases, and fails to reveal a maternal bias in
the inheritance of familial PD. The question of maternal
inheritance in PD has been controversial, with some stu-
dies reporting a bias towards maternal inheritance in PD
[5,6], and others failing to find this pattern [7,8]. Differ-
ences in methodologies and patient populations may
contribute to the disparate results. De Michele et al [7]
reported that secondary cases of 100 PD patients were
more common in the paternal versus maternal line (70
versus 39). A questionnaire administered to 252 PD
patients by Zweig and colleagues [8] identified 11
fathers and 5 mothers reported to have PD. Swerdlow
and colleagues [5] subsequently addressed this issue in a
larger set of 600 PD probands in their clinical database.
They identified an affected parent in 13% of cases.
Though 60% of the probands were male, only 42% of
the affected parents were male, indicating an increased
representation of females among parents with PD com-
pared to the probands with PD (p < 0.005). Wooten et
al [6] used a different approach, prospectively identifying
families with an affected parent and multiple affected
siblings. 57% of all PD cases in their database were
male. The mother was the affected parent in all 5 of the
first 5 such families, which represents a greater repre-
sentation of females than expected if there was no gen-
der effect (p < 0.03). Maher et al [41] reported that 60%
of the probands among 948 consecutively ascertained
PD cases were male whereas a greater percentage of
affected parents were mothers compared to fathers (68
mothers versus 48 fathers; p = 0.0001 two-tailed Fisher
exact p comparing male:female ratios in probands versus
affected parents).
The current study failed to detect a significant bias
towards maternal inheritance in familial PD, adding
additional uncertainty regarding the role of inherited
Table 3 Association results for risk and gender of affected parent
Fisher’s Exact Test McNemar’s Test Fisher’s Exact Test
Allele Cases Controls p Risk p Affected Mother Affected Father p
1719A 93.4% 95.9% 0.09 - 0.11 90.0% 91.0% 0.83
4580A 97.2% 97.4% 0.84 - 1.00 95.0% 98.5% 0.24
7028C 54.1% 55.3% 0.69 - 0.74 61.3% 53.7% 0.36
8251A 94.9% 95.1% 0.88 - 1.00 87.5% 95.5% 0.09
9055A 92.3% 90.2% 0.25 + 0.29 96.2% 89.6% 0.11
10398G 19.4% 20.9% 0.57 - 0.62 20.0% 20.9% 0.89
10400T 0.6% 0.4% 0.65 + 1.00 0.0% 1.5% 0.27
12308G 21.4% 23.3% 0.48 - 0.52 21.2% 23.9% 0.70
13368A 89.5% 91.2% 0.38 - 0.44 91.2% 92.5% 0.78
13708A 88.0% 86.8% 0.55 + 0.61 86.2% 91.0% 0.37
16391A 98.1% 97.4% 0.51 + 0.66 95.0% 98.5% 0.24
H 43.6% 42.9% 0.84 + 0.90 36.2% 46.3% 0.22
I 1.7% 2.4% 0.49 - 0.65 5.0% 0.0% 0.06
J 9.2% 10.9% 0.38 - 0.43 12.5% 7.5% 0.31
K 7.5% 9.4% 0.29 - 0.34 3.8% 10.4% 0.11
M 0.6% 0.4% 0.65 + 1.00 0.0% 1.5% 0.27
T 9.4% 8.3% 0.57 + 0.65 8.8% 6.0% 0.52
U 12.6% 13.0% 0.84 - 0.92 17.5% 10.4% 0.22
V 2.4% 2.4% 1.00 - 1.00 3.8% 1.5% 0.40
W 1.7% 1.7% 1.00 - 1.00 3.8% 1.5% 0.40
X 2.8% 0.6% 0.01 + 0.02 1.2% 7.5% 0.06
Other 8.5% 7.9% 0.72 + 0.81 7.5% 7.5% 0.99
IJK vs. HMTUVWX 18.4% 22.6% 0.11 - 0.12 21.2% 17.9% 0.61
JTUK vs. HIMVWX 31.2% 33.1% 0.53 - 0.57 35.0% 26.9% 0.29
JTIWX vs. HKMUV 24.8% 23.9% 0.76 + 0.82 31.2% 22.4% 0.23
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mtDNA variants in PD. A potential concern for this
study is that the stronger genetic influence in familial
PD cases might have led to a closer to 50:50 ratio of
males to females in contrast to the male predominance
for sporadic PD. However, this observation is unlikely to
be a factor in this study as siblings and parents came
from the same families. To improve the ability to detect
an influence of mtDNA genetic variants, all families
with known causative mutations in the PARK2 or
LRRK2 genes (either two PARK2 mutations or one
LRRK2 mutation), [42,43] were excluded from these
analyses. Most of the samples were not screened for
mutations in other PD-associated genes such as PINK1
and DJ1, but such mutations are relatively rare [44].
Mitochondrial genes are passed on from mothers to
offspring but not from fathers to offspring. Therefore, to
the degree that heritable mitochondrial genetic factors
influence the risk of PD, there should be a greater risk
of PD among offspring of women with PD compared to
offspring of men with PD. However, alternative mechan-
isms also could result in a maternal inheritance bias.
One example is epigenetic changes (imprinting) of auto-
somal genes. An additional potential mechanism is in
utero environmental factors [45], as suggested by data
demonstrating delayed loss of dopaminergic neurons fol-
lowing in utero exposure to lipopolysaccharide in
rodents [46,47]. Another consideration is that histori-
cally women tend to live longer than men and are more
likely to develop age-related diseases. Another possibility
is that women affected with PD could be more likely to
have a stronger genetic influence on the disease com-
pared to men with PD. However, despite these addi-
tional possible causes of a maternal inheritance pattern
in PD, we did not detect this pattern in our study
population.
Indirect data has implicated mtDNA in the mitochon-
drial complex I defect in PD. “Cybrid” cell lines expres-
sing mtDNA from PD patients manifest impaired
mitochondrial complex I activity [9,10], suggesting that
the complex I defect in PD results from stable differ-
ences in mtDNA. One possible explanation for these
results from studies of cybrids despite a lack of consis-
tent evidence for maternal inheritance in PD is that
somatic mtDNA mutations rather than inherited muta-
tions might account for the complex I defect in PD [48].
Heteroplasmic somatic mutations may be individually
rare, but could accumulate to reach functionally signifi-
cant levels in aggregate, though they would not be reli-
ably detected with the genotyping methods used in the
current study. Alternatively, the role of inherited
mtDNA mutations, which can be sporadically expressed,
may be different in sporadic PD compared to familial
PD, with a greater influence of nuclear genetic factors
influencing familial PD.
Another way to test a role for mtDNA variants in PD,
in addition to testing for a maternal inheritance pattern,
is to compare the frequencies of mtDNA variants
between cases and controls. Prior studies of mitochon-
drial variants in PD have failed to identify clearly patho-
genic mutations in the vast majority of patients [19,20],
but these prior studies did not adequately address the
possibility of a milder influence on PD risk from more
common mtDNA variants. Our results add to the uncer-
tainty regarding the previously reported association of
the 10398G mitochondrial complex I gene polymorph-
ism with a lower risk of PD [25,32]. Van der Walt and
colleagues reported a reduced frequency of this poly-
morphism in Caucasian PD patients, suggesting a pro-
tective effect [32], and this inverse association was
confirmed in a subsequent study in Spanish patients
Table 4 Association results for age at onset






1719A 61.7 63.2 0.52 61.8 64.4 0.16
4580A 61.8 60.4 0.61 62 61.1 0.76
7028C 61.2 62.4 0.21 61.5 62.5 0.28
8251A 61.9 59.2 0.20 62.1 59.5 0.20
9055A 62.0 59.8 0.22 62.1 60.2 0.26
10398G 60.3 62.2 0.11 60.6 62.3 0.15
10400T 57.7 61.8 0.48 60.2 62.0 0.75
12308G 60.2 62.2 0.08 59.8 62.5 0.01
13368A 61.6 63.7 0.17 61.7 63.8 0.17
13708A 61.8 62.0 0.86 62.0 61.9 0.98
16391A 61.9 58.9 0.39 62.0 58.3 0.26
H 62.2 61.5 0.49 62.4 61.6 0.41
I 59.6 61.8 0.54 59.3 62.0 0.45
J 61.4 61.8 0.80 61.7 62.0 0.89
K 59.6 62.0 0.18 60.0 62.1 0.22
M 57.7 61.8 0.48 60.2 62.0 0.75
T 63.7 61.6 0.20 63.6 61.8 0.23
U 60.4 62.0 0.26 59.4 62.3 0.03
V 60.9 61.8 0.77 61.3 62.0 0.83
W 60.2 61.8 0.67 58.9 62.0 0.38
X 65.2 61.7 0.45 67.1 61.8 0.06
Other 62.6 61.7 0.63 63.3 61.8 0.35
IJK vs.
HMTUVWX
60.5 62.1 0.19 60.8 62.2 0.23
JTUK vs.
HIMVWX
61.1 62.1 0.35 60.8 62.5 0.09
JTIWX vs.
HKMUV
62.5 61.6 0.41 62.7 61.7 0.34
1 Since all siblings share the same mitochondrial SNP alleles and therefore
haplogroups, testing for association with the mean age at onset of all affected
siblings in a nuclear family is a valid and more powerful test. The number of
affected siblings in a family ranged from 1 to 5.
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[25]. However, a previous study found no association of
the 10398G variant with the risk of PD in the subset of
Caucasian subjects in that study [19], and a later study
in Italian subjects similarly detected no association of
this variant with PD [24]. The current study, which
included only Caucasian subjects, also failed to identify
a significant association of the 10398G variant with the
risk of PD, and furthermore failed to reveal an associa-
tion of this variant with the age of onset of PD. Variabil-
ity in the reported association of the 10398G variant
with PD could relate to distinct subject populations
across studies, and thus further studies are needed to
determine if this polymorphism may influence the risk
of PD in certain subsets of PD patients.
Reports of a possible association of haplogroups J and
K with PD have been inconsistent [24,27,29-32]. Mito-
chondrial haplogroup clusters also variably have been
reported to be associated with an increased (JT [31];
JTIWX [26]) or decreased (UKJT [27,40]) risk of PD,
while others have failed to detect a significant associa-
tion of UKJT [29]. In the current study of Caucasian
familial PD subjects, we did not find evidence for an
association of any mitochondrial haplogroup with the
risk of PD or with age of onset of PD. Several factors,
including distinct populations, different numbers of sub-
jects, and distinct methods of analyses may contribute
to the variability in results across studies. One major
strength of the study is the one-to-one matching of
cases and controls based on ethnicity (Figure 1). Popula-
tion stratification is always a concern for genetic asso-
ciation studies, and if the frequency of specific
haplogroups varies between Caucasians with different
ancestries (e.g. Northern European versus Southern Eur-
opean versus Ashkenazi), then previous association
results may be purely the result of admixture within the
study population and therefore spurious.
Conclusions
We did not detect a maternal bias in the inheritance of
PD among PROGENI subjects, and failed to confirm
previously reported associations of inherited mtDNA
variants with PD risk. This suggests that other factors,
possibly including somatic mtDNA mutations, may
account for the complex I defect in PD.
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